Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus

Novo Nordisk's FDA-approved weight-loss pill intensifies its rivalry with Eli Lilly, putting health care and biotech ETFs in focus.

Lilly, Novo lock horns in India's obesity drug race

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit

Novo Nordisk Shares Jump After US Approves Wegovy Pill

Dec 23 (Reuters) - Novo Nordisk shares jumped ‌10% ​on Tuesday after the U.S. Food and ‌Drug Administration approved its weight-loss pill, giving the Danish drugmaker a competitive edge over rival ​Eli Lilly in the fast-evolving market for obesity drugs.

These stocks moved the most today: Novo Nordisk, ServiceNow, Micron, DJT, Freeport-McMoRan, Zim, and more

Bond yields jumped after the report, and the S&P 500 was set to close at a record high.These stocks were moving Tuesday:U.S.-listed shares in Danish drugmaker Novo Nordisk rose 6.5% after the Food and Drug Administration approved the first GLP-1 pill,

Stocks to Watch Tuesday: Novo Nordisk, Huntington Ingalls, ServiceNow

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing approval from U.S. regulators](

Novo Nordisk's new obesity pill, Alphabet's data center deal, the end of EV euphoria and more in Morning Squawk

Regulators approved the first-ever GLP-1 pill for treating obesity from Novo Nordisk. Alphabet will acquire data center company Intersect for $4.75 billion in cash and assume its debt. Instacart is ending its contentious AI-driven pricing tests.
Feedback